Heat shock proteins (HSP) are a family of highly conserved proteins, whose expression increases in response to stresses that may threaten cell survival. Over the past decade, heat shock protein 90 (Hsp90) has emerged as a potential therapeutic target for cancer as it plays a vital role in normal cell maturation and acts as a molecular chaperone for proper folding, assembly, and stabilization of many oncogenic proteins. To date, a majority of Hsp90 inhibitors that have been discovered are macrocycles. The relatively rigid conformation provided by the macrocyclic scaffold allows for a selective interaction with a biological target such as Hsp90. This review highlights the discovery and development of nine macrocycles that inhibit the function of Hsp90, detailing their potency and the client proteins affected by Hsp90 inhibition.
Heat shock proteins (n class="Gene">HSP) are a family of highly conserved proteins, whose expression increases in response to stresses that may threaten cell survival. Over the past decade, heat shock protein 90 (Hsp90) has emerged as a potential therapeutic target for cancer as it plays a vital role in normal cell maturation and acts as a molecular chaperone for proper folding, assembly, and stabilization of many oncogenic proteins. To date, a majority of Hsp90 inhibitors that have been discovered are macrocycles. The relatively rigid conformation provided by the macrocyclic scaffold allows for a selective interaction with a biological target such as Hsp90. This review highlights the discovery and development of nine macrocycles that inhibit the function of Hsp90, detailing their potency and the client proteins affected by Hsp90 inhibition.
Authors: Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stanley Kaye; Paul Workman; Ian Judson Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: David B Solit; Fuzhong F Zheng; Maria Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Georgios V Georgakis; Yang Li; Georgios Z Rassidakis; Hector Martinez-Valdez; L Jeffrey Medeiros; Anas Younes Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Merrill J Egorin; Theodore F Lagattuta; Deborah R Hamburger; Joseph M Covey; Kevin D White; Steven M Musser; Julie L Eiseman Journal: Cancer Chemother Pharmacol Date: 2002-01 Impact factor: 3.333
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Robert P Sellers; Leslie D Alexander; Victoria A Johnson; Chun-Chieh Lin; Jeremiah Savage; Ricardo Corral; Jason Moss; Tim S Slugocki; Erinprit K Singh; Melinda R Davis; Suchitra Ravula; Jamie E Spicer; Jenna L Oelrich; Andrea Thornquist; Chung-Mao Pan; Shelli R McAlpine Journal: Bioorg Med Chem Date: 2010-07-22 Impact factor: 3.641
Authors: Y Zhang; S Dayalan Naidu; K Samarasinghe; G C Van Hecke; A Pheely; T N Boronina; R N Cole; I J Benjamin; P A Cole; Y-H Ahn; A T Dinkova-Kostova Journal: Br J Cancer Date: 2013-12-05 Impact factor: 7.640